[HTML][HTML] Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
Y Osugi, H Iwata, Y Imai, D Kobayashi, R Hirashima - Cureus, 2022 - ncbi.nlm.nih.gov
Aim: This study aimed to report clinical courses of patients who had mild coronavirus
disease 2019 (COVID-19), defined as SpO 2 of 96 or higher, and treated with/without …
disease 2019 (COVID-19), defined as SpO 2 of 96 or higher, and treated with/without …
[PDF][PDF] Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
Y Osugi, H Iwata, Y Imai, D Kobayashi, R Hirashima - Cureus, 2022 - cureus.com
Aim: This study aimed to report clinical courses of patients who had mild coronavirus
disease 2019 (COVID-19), defined as SpO2 of 96 or higher, and treated with/without …
disease 2019 (COVID-19), defined as SpO2 of 96 or higher, and treated with/without …
Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
O Yasuhiro, I Hitoshi, I Yasushi, K Daiki, H Ryutaro - Cureus, 2022 - search.proquest.com
Aim: This study aimed to report clinical courses of patients who had mild coronavirus
disease 2019 (COVID-19), defined as SpO 2 of 96 or higher, and treated with/without …
disease 2019 (COVID-19), defined as SpO 2 of 96 or higher, and treated with/without …
[PDF][PDF] Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
Y Osugi, H Iwata, Y Imai, D Kobayashi, R Hirashima - 2022 - scienceopen.com
Aim: This study aimed to report clinical courses of patients who had mild coronavirus
disease 2019 (COVID-19), defined as SpO2 of 96 or higher, and treated with/without …
disease 2019 (COVID-19), defined as SpO2 of 96 or higher, and treated with/without …
Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan.
Y Osugi, H Iwata, Y Imai, D Kobayashi, R Hirashima - Cureus, 2022 - europepmc.org
Aim This study aimed to report clinical courses of patients who had mild coronavirus disease
2019 (COVID-19), defined as SpO 2 of 96 or higher, and treated with/without casirivimab …
2019 (COVID-19), defined as SpO 2 of 96 or higher, and treated with/without casirivimab …
[PDF][PDF] Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
Y Osugi, H Iwata, Y Imai, D Kobayashi, R Hirashima - 2022 - assets.cureus.com
Aim: This study aimed to report clinical courses of patients who had mild coronavirus
disease 2019 (COVID-19), defined as SpO2 of 96 or higher, and treated with/without …
disease 2019 (COVID-19), defined as SpO2 of 96 or higher, and treated with/without …
Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
Y Osugi, H Iwata, Y Imai, D Kobayashi… - Cureus, 2022 - pubmed.ncbi.nlm.nih.gov
Aim This study aimed to report clinical courses of patients who had mild coronavirus disease
2019 (COVID-19), defined as SpO 2 of 96 or higher, and treated with/without casirivimab …
2019 (COVID-19), defined as SpO 2 of 96 or higher, and treated with/without casirivimab …
[PDF][PDF] Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan
Y Osugi, H Iwata, Y Imai, D Kobayashi, R Hirashima - 2022 - assets.cureus.com
Aim: This study aimed to report clinical courses of patients who had mild coronavirus
disease 2019 (COVID-19), defined as SpO2 of 96 or higher, and treated with/without …
disease 2019 (COVID-19), defined as SpO2 of 96 or higher, and treated with/without …
Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan.
Y Osugi, H Iwata, Y Imai, D Kobayashi, R Hirashima - Cureus, 2022 - europepmc.org
Aim This study aimed to report clinical courses of patients who had mild coronavirus disease
2019 (COVID-19), defined as SpO 2 of 96 or higher, and treated with/without casirivimab …
2019 (COVID-19), defined as SpO 2 of 96 or higher, and treated with/without casirivimab …